gsk3352589
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2017 (NCT03154086)
Timeline
Indications
Studied for
Mechanism of action
RET inhibitor
- Tyrosine-protein kinase receptor RETINHIBITOR
Tyrosine-protein kinase receptor RET inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650296 ↗
Also known as
- gsk3352589
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03977155 | Phase 2 | Jun 4, 2019 | Boston Pharmaceuticals |
| NCT03154086 | Phase 1 | May 17, 2017 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1